Zheng et al. [30] conducted a retrospective study in patients with RA and found that serum KL-6 and tumor marker (CEA, CA153, and CA19-9) levels were elevated in patients with RA-ILD and were associated with ILD severity, supporting the clinical value of these markers as disease-related biomarkers. The gene discussed is CEACAM5; the disease is neoplasm.